Tasigna - 2007 FDA approvals

Drug: Tasigna (nilotinib)
Indication: Chronic myeloid leukemia
Company: Novartis
Approval Date: October 29, 2007

Scoop: Novartis has won FDA approval of Tasigna for patients with chronic myeloid leukemia who are resistant to Gleevec. Tasigna works by inhibiting the proliferation of cells containing an abnormal chromosome called the Philadelphia chromosome.

More News:
Novartis wins FDA approval for Tasigna. Report

Tasigna - 2007 FDA approvals

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i